Mike Cloonan, Sionna Therapeutics CEO
Sionna raises $182M for cystic fibrosis drugs different from Vertex's approach
Sionna Therapeutics has raised $182 million in a Series C to test its small molecules for cystic fibrosis by targeting the mutated region of the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
